Comparing Opioid-Related Deaths Among Cancer Survivors, General Population

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, MAY 7, 2020

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.0799?guestAccessKey=dd16d617-9706-4e4c-8702-a30d13057c2a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050720

 

What The Study Did: Death certificate data were used to compare the rate of opioid-related deaths in the U.S. among cancer survivors with that of the general population from 2006 through 2016. Whether opioid-associated deaths in cancer survivors, who are often prescribed opioids for cancer-related pain, are rising at the same rate as in the general population is unknown.

Authors: Fumiko Chino, M.D., of the Memorial Sloan Kettering Cancer Center in New York, is the corresponding author.

 

(doi:10.1001/jamaoncol.2020.0799)

Editor’s Note: The article includes conflict of interest disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.